Specialty nephrology ICD-9-CM 586 | ICD-10 N99.0 | |
Contrast-induced nephropathy (CIN) is defined as either a greater than 25% increase of serum creatinine or an absolute increase in serum creatinine of 0.5 mg/dL after using iodine contrast agent without another clear cause for kidney injury. Despite extensive speculation, the actual occurrence of contrast-induced nephropathy has not been demonstrated in the literature. The mechanism of contrast-induced nephropathy is not entirely understood, but is thought to include direct toxicity of reactive oxygen species, contrast-induced diuresis, increased oxygen consumption, changes in vasodilation and vasoconstriction, and changes in urine viscosity.
Contents
Risk factors
To minimize the risk for contrast-induced nephropathy, various actions can be taken if the patient has predisposing conditions. These have been reviewed in a meta-analysis. A separate meta-analysis addresses interventions for emergency patients with baseline insufficient kidney function.
Individuals with chronic kidney disease, diabetes mellitus, high blood pressure, reduced intravascular volume, or who are elderly are at increased risk of developing CIN after exposure to iodinated contrast.
A clinical prediction rule is available to estimate probability of nephropathy (increase ≥25% and/or ≥0.5 mg/dl in serum creatinine at 48 h):
Risk Factors:
Scoring:
5 or less points
6–10 points
11–16 points
>16 points
Contrast agent
The osmolality of the contrast agent was previously believed to be an important factor in contrast-induced nephropathy. Today it has become increasingly clear that other physicochemical properties play a greater role, such as viscosity. Attention should be paid to using contrast agents of low viscosity. Moreover, sufficient fluids should be supplied to limit fluid viscosity of urine. Modern iodinated contrast agents are non-ionic, the older ionic types caused more adverse effects, and their use has diminished.
Prevention
Evidence supports the use of N-acetylcysteine with intravenous saline among those getting low molecular weight contrast. The use of statins with N-acetylcysteine and intravenous saline is also supported.
Methylxanthines
Adenosine antagonists such as the methylxanthines theophylline and aminophylline, may help although studies have conflicting results.
N-acetylcysteine
N-acetylcysteine (NAC) by mouth twice a day, on the day before and of the procedure if creatinine clearance is estimated to be less than 60 mL/min [1.00 mL/s]) may reduce risk. Some authors believe the benefit is not overwhelming. A systematic review concluded that NAC is "likely to be beneficial" but did not recommend a specific dose.
Ascorbic acid
Ascorbic acid may be protective against CIN, according to a systematic review of randomized controlled trials.
Research
While there are currently no FDA-approved therapies for contrast-induced nephropathy, two therapies are currently being investigated. CorMedix is currently in the latter part of phase II clinical trials with approved phase III Special Protocol Assessment for CRMD001 (unique formulation Deferiprone) to prevent contrast-induced acute kidney injury and to slow progression of chronic kidney disease. Dosing trials began in June 2010 in the sixty patient trial.
There is also a phase III clinical trial of RenalGuard Therapy to prevent contrast-induced nephropathy. The therapy utilizes the RenalGuard System, which measures the patient's urine output and infuses an equal volume of normal saline in real-time. The therapy involves connecting the patient to the RenalGuard System, then injecting a low dose of furosemide to induce high urine output rates.